As of 2026-07-30 | NASDAQ: GILD | Biotechnology
| Metric / Component | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | B | 72 | Balanced growth-value hybrid with earnings acceleration offset by elevated forward valuation; defensive beta (0.33) mitigates sector volatility | 6–12M |
| SA Quality/Value Composite | B+ | 78 | Profitable (EPS: $7.35), low volatility (β=0.33), 2.47% yield, PEG=0.35 signals undervaluation at current earnings growth rate | Ongoing |
| Zacks Earnings Momentum | A− | 85 | EPS growth YoY: +55.49% (hyper-growth flag active); forward PE 31.07x suggests market pricing elevated future expectations | 1–3M |
| Institutional & Smart Money Flow | B | 70 | 52-week return +16.20% (outpacing biotech baseline); current pullback (−1.90% session, off 52W high $157.29) may reflect profit-taking or pipeline hesitation | 1–3M |
| Growth Sustainability & Moat | B | 73 | Revenue growth modest (YoY +3.48%); EPS growth (+55.49%) driven by margin expansion or share buyback rather than topline acceleration; data gaps on R&D pipeline limit forward visibility | 6–12M |
| Valuation & Safety (Pre-Penalty) | B− | 68 | Trailing PE 19.57x fair for biotech; forward PE 31.07x elevated; PEG 0.35 attractive given EPS momentum; market cap $166.5B anchors institutional participation | Ongoing |
| Penalty Overlay | −5 | −5 | Forward PE stretch (31.07x) relative to historical norms; earnings date and target price data unavailable; revenue stagnation risk if pipeline disappoints | 3–6M |
| CONFIDENCE SCORE | B | 74 | Strong quantitative metrics (earnings, dividend, low beta); gaps in earnings guidance, pipeline clarity, and balance sheet detail create moderate uncertainty | Ongoing |
| Volatility & Drawdown Risk | A− | 82 | Beta 0.33 places GILD in low-volatility cohort; 52-week range $108.46–$157.29 (44.8% span) moderate; dividend cushion at 2.47% reduces downside asymmetry | Ongoing |
| Crowding Risk Flag | B− | 65 | Strong YTD return (+16.20%) and institutional market cap suggest moderate crowding; forward PE multiple expansion may invite mean-reversion selling if earnings fail to deliver | 3–6M |
GILD trades in the large-cap biotechnology cohort alongside AMGN, BIIB, REGN, and VRTX. Its defensive beta (0.33) places it in the lower-volatility subset—more characteristic of mature pharma than high-growth biotech. The 52-week return of +16.2% trails mega-cap pharma indices but exceeds biopharma peers with higher pipeline risk. Forward PE of 31.07x now sits above historical biotech median (25–28x), suggesting market consensus has fully priced near-term earnings acceleration (+55.49% YoY). Dividend yield (2.47%) is notably competitive for the sector, signaling cash generation maturity.
Near-term catalysts likely center on earnings guidance reaffirmation or pipeline announcements. Current session pullback (−1.90%) off 52W highs suggests profit-taking and potential mean-reversion pressure. Forward PE expansion (31.07x) carries execution risk; any earnings miss could trigger sharper correction. Monitor for analyst revisions and institutional accumulation patterns. Low beta (0.33) provides technical support.
Fundamental thesis hinges on whether EPS growth can sustain above 50% CAGR. Revenue stagnation (YoY +3.48%) is the key structural concern—earnings accretion appears driven by margin expansion or capital allocation rather than organic topline strength. If revenue remains flat and EPS growth normalizes toward 15–20% over the next 12 months, forward PE compression is likely. Conversely, if management announces significant pipeline approvals or M&A, upside to $145–150 is plausible. Dividend stability and buyback consistency will support a floor near current levels.
| Risk Factor | Severity | Note |
|---|---|---|
| Earnings Deceleration | MEDIUM | EPS growth of +55% is unsustainable. Forward guidance and pipeline visibility are critical to assess Q4/FY2027 momentum. |
| Forward Valuation Stretch | MEDIUM | 31.07x forward PE above historical range; vulnerable to multiple compression if growth disappoints. |
| Revenue Plateau | MEDIUM | YoY revenue growth of +3.48% signals mature product cycle; new product uptake unclear due to data gaps. |
| Volatility & Drawdown | LOW | Beta 0.33 and dividend support downside cushion; 52W range suggests $120–$125 floor support. |
| Institutional Crowding | MODERATE | Large market cap ($166.5B) and strong recent return may concentrate retail/ETF flows; momentum-sensitive. |
GILD is a defensive, dividend-yielding biotech name with compelling valuation (PEG 0.35) undermined by forward PE stretch (31.07x) and revenue stagnation. Earnings momentum remains strong (+55% YoY), but sustainability unclear without pipeline disclosure. Institutional-quality balance sheet and low volatility (β=0.33) suit conservative mandates. Recommend ACCUMULATE on weakness, HOLD at current levels. Earnings catalyst and revenue guidance will be make-or-break for next leg.
GILD Systematic Research
Gilead Sciences demonstrates exceptional profitability metrics that distinguish it within the biotechnology sector, with a return on equity of 42.21% and net margin of 31.0% substantially exceeding typical industry benchmarks. The company's gross margin of 79.35% reflects significant pricing power in its therapeutic franchises, while operating margin of 34.88% indicates disciplined expense management across R&D and commercial operations.
The valuation profile presents a mixed picture at current levels. Trading at a P/E ratio of 17.55, the multiple appears moderate relative to the biotech peer group, particularly given the firm's profitability strength. However, the P/B ratio of 6.71 suggests premium valuation relative to tangible book value of $18.29 per share. The recent EPS growth of 55.49% year-over-year contrasts sharply with revenue expansion of just 3.48%, pointing to margin improvement and operational leverage rather than top-line acceleration as the primary earnings driver.
Systematic screening highlights several considerations for the research perspective:
- Beta of 0.34 positions the equity as a defensive holding with significantly lower volatility than broader market indices
- Debt-to-equity of 1.1 reflects moderate leverage, manageable given the strong cash generation implied by profitability metrics
- Current ratio of 1.55 provides adequate liquidity coverage
- Revenue growth deceleration remains a watchpoint, as modest 3.48% expansion may indicate maturation in core product franchises
Against peers including ABBV, the company's superior ROE and defensive beta characteristics differentiate its fundamental profile, though the revenue growth trajectory warrants ongoing monitoring within portfolio allocation frameworks.
Analysis updated monthly based on systematic screening of fundamentals, profitability, growth, and peer positioning.
Install ESEN on iPhone
Apple requires manual install. Follow these 3 steps yourself: